Market Outlook

By 2035, the U.S. Connected Diabetes Care Devices Market is estimated to reach approximately USD 37.70 billion, expanding at an aggressive CAGR of 13.80% during the forecast period 2026–2035. The market is estimated at USD 10.35 billion in 2025, following rapid historical expansion from approximately USD 4.24 billion in 2021, USD 5.22 billion in 2022, USD 6.55 billion in 2023, and USD 8.18 billion in 2024. Values in this report are expressed in USD billions.

For the purpose of this report, connected diabetes care devices include continuous glucose monitoring systems, connected blood glucose meters, automated and digitally connected insulin delivery systems, smart insulin pens and connected injection technologies, and the device-linked software, receivers, controllers and data infrastructure required for those systems to function. Standalone telehealth, general wellness applications and diabetes coaching services without an integral connected-device component are excluded to avoid overstating the medical-device opportunity.

The market is moving from periodic glucose testing and manually calculated insulin dosing toward continuous sensing, algorithm-assisted treatment and increasingly automated therapy. This transition is occurring against a very large clinical base. The latest U.S. national estimates indicate approximately 40.1 million people had diagnosed or undiagnosed diabetes in 2023, representing about 12.0% of the population, while approximately 115.2 million adults had prediabetes. About 2.1 million Americans had diagnosed type 1 diabetes.

The economic burden also supports continued investment in better disease-management technology. Diagnosed diabetes generated an estimated USD 412.9 billion in total U.S. economic costs in 2022, including USD 306.6 billion in direct medical costs and USD 106.3 billion in indirect costs. Average medical expenditures among people with diagnosed diabetes were approximately 2.6 times those expected in the absence of diabetes after adjustment for age and sex.

The addressable connected-device market is expanding beyond the traditional type 1 insulin-pump population. CGM adoption is moving deeper into insulin-treated type 2 diabetes, basal-insulin therapy, non-insulin-treated type 2 diabetes and selected metabolic-health applications. Automated insulin delivery is following a similar trajectory. In August 2024, the FDA expanded Insulet SmartAdjust technology to adults with type 2 diabetes, marking the first FDA-cleared automated insulin-dosing technology for this population.

Commercial evidence confirms that connected diabetes technology has already become a multi-billion-dollar device category rather than an emerging digital-health niche. Dexcom generated approximately USD 3.33 billion of U.S. revenue in 2025, Insulet generated approximately USD 1.9 billion of U.S. Omnipod revenue, and Tandem Diabetes Care reported approximately USD 706.9 million of U.S. sales. Abbott, which does not separately disclose U.S. CGM sales, reported approximately USD 7.6 billion in worldwide CGM sales during 2025, up from USD 6.4 billion in 2024.

These commercial benchmarks underpin the 2025 market estimate and support a double-digit forecast. The next stage of value creation will increasingly be determined by sensor wear duration, affordability, pharmacy access, interoperability, type 2 penetration, automated dosing, smartphone control, clinical workflow integration and the ability to convert continuous glucose data into actionable therapeutic decisions.

 

Introduction

According to the U.S. Connected Diabetes Care Devices Market Report, diabetes care in the United States is entering a structurally different technology cycle. For decades, device demand was primarily defined by fingerstick blood glucose measurement, insulin syringes, conventional pens and standalone insulin pumps. The market is now being reorganized around continuous data flows between the patient, sensor, insulin-delivery device, smartphone, caregiver and healthcare professional.

This connectivity matters because diabetes requires thousands of decisions over a patient’s lifetime. Glucose levels change continuously in response to meals, physical activity, medication, sleep, illness, stress and numerous other factors. Connected technology reduces reliance on isolated readings and allows trends to be interpreted in real time. At the more advanced end of the market, CGM readings are transmitted directly to automated insulin-delivery algorithms, which can increase, decrease or suspend insulin according to predicted glucose trajectories.

The U.S. is particularly attractive for connected diabetes technology because it combines a large diabetes population with sophisticated endocrinology networks, widespread smartphone usage, established pharmacy distribution, durable medical equipment infrastructure, commercial insurance coverage, Medicare reimbursement and high clinical familiarity with CGM. Medicare Part B currently covers CGMs and related supplies for eligible beneficiaries with diabetes when prescribed according to FDA indications and when the patient is insulin-treated or has a documented history of problematic hypoglycemia.

Reimbursement design strongly influences the competitive landscape. Durable insulin pumps can be covered under Medicare Part B, while disposable patch pumps such as Omnipod generally operate under different benefit pathways, including drug-plan coverage. This difference affects patient acquisition, manufacturer contracting, channel economics and provider prescribing behavior.

At the same time, connected diabetes care is becoming less endocrinology-dependent. The largest future patient opportunity lies in type 2 diabetes, where treatment frequently occurs in primary care rather than specialty clinics. Successful devices must therefore become easier to prescribe, easier to initiate and less operationally demanding for providers. Product companies that require substantial training, prior authorization work or specialized technical support may face adoption friction outside high-volume diabetes centers.

From 2026 through 2035, connected diabetes care is expected to evolve from device connectivity to therapeutic orchestration. A Bluetooth-enabled glucose meter transmitting readings to an application qualifies as connected care, but the highest-value systems will increasingly combine glucose sensing, predictive analytics, medication information, dosing support, remote monitoring and automated insulin delivery. In this environment, the competitive advantage shifts from individual hardware specifications toward the quality of the entire clinical and data ecosystem.

 

Key Market Drivers: What’s Fueling the U.S. Connected Diabetes Care Devices Market Boom?

The first structural driver is the scale of the U.S. diabetes and prediabetes population. Approximately 40.1 million Americans were estimated to have diabetes in 2023, while another 115.2 million adults had prediabetes. This creates a potential user base far larger than the historically targeted population of people with type 1 diabetes using intensive insulin therapy.

The second driver is continuous glucose monitoring moving toward mainstream diabetes management. CGM eliminates much of the informational limitation associated with intermittent fingerstick testing by revealing glucose direction, variability, overnight patterns and post-meal responses. Connected CGM systems also facilitate remote data sharing with clinicians and caregivers. Commercial momentum is substantial: Abbott’s global CGM revenue reached USD 7.6 billion in 2025, while Dexcom’s worldwide revenue reached USD 4.66 billion, including USD 3.33 billion generated in the United States.

A third major driver is automated insulin delivery entering type 2 diabetes. The economic significance of this transition is substantial because the type 2 population is dramatically larger than the type 1 population. FDA expansion of Insulet’s SmartAdjust indication in 2024 created the first U.S. automated insulin-dosing option for adults with type 2 diabetes, while Tandem’s Control-IQ+ received FDA clearance for adults with type 2 diabetes in February 2025. Tandem indicated that more than two million people in the United States rely on intensive insulin therapy for type 2 diabetes, illustrating the scale of the immediately addressable population.

The fourth driver is reimbursement expansion and improved channel accessibility. Medicare coverage of CGM for insulin-treated individuals and people with problematic hypoglycemia increases technology access among older adults, who represent an important diabetes cohort. Pharmacy distribution is simultaneously reducing some of the logistical friction historically associated with durable medical equipment. Manufacturers increasingly design commercial models around prescription simplification, automated insurance verification, pharmacy availability and recurring consumable fulfillment.

The fifth driver is the migration of diabetes care toward the home. Most glucose monitoring, insulin administration and disease-management decisions occur outside hospitals. Connected devices transform the home into a longitudinal data-generating care environment. Health systems and physician practices can review glucose patterns without requiring the patient to reproduce paper logs or manually download meters during appointments. This supports more efficient clinical review and can make virtual diabetes management more practical.

A sixth driver is consumerization without complete separation from medical care. FDA clearance of Dexcom Stelo in March 2024 created the first over-the-counter CGM in the United States for adults who do not use insulin. This opened a direct pathway to individuals with type 2 diabetes managed without insulin and to consumers seeking greater insight into metabolic responses. The subsequent 2026 expansion of OTC Stelo to individuals aged two years and older who do not use insulin further illustrates how the connected glucose-sensing market is moving beyond traditional prescription-only boundaries.

The seventh driver is the growing economics of recurring consumables. Connected diabetes care is financially attractive because many systems generate continuous sensor, infusion-set, pod, cartridge or other consumable revenue after initial patient acquisition. This recurring model provides manufacturers with greater lifetime customer value than one-time hardware sales and encourages investment in patient retention, mobile applications, customer support and interoperability.

Finally, healthcare providers and payers are placing increasing emphasis on measurable outcomes rather than device ownership alone. Connected systems generate time-in-range, glucose management indicators, hypoglycemia exposure, adherence information and treatment-response data that can support more informed clinical management. Manufacturers capable of showing improved glycemic outcomes, simplified workflows and reduced treatment burden can defend premium pricing more effectively than companies competing only on hardware cost.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation is shifting from isolated diabetes devices toward interoperable therapeutic systems. Modern connected diabetes platforms increasingly consist of a sensor, dosing algorithm, pump or injection device, smartphone interface, cloud platform and clinician-facing analytics layer. The strategic objective is to reduce the number of decisions the user has to make while increasing the quality of information available to both patient and clinician.

Automated insulin delivery is one of the most important innovation fronts. These systems use CGM information to continually modify insulin delivery. Regulatory expansion into type 2 diabetes is especially important. Insulet received the first U.S. type 2 indication for interoperable automated dosing in 2024, followed by Tandem’s Control-IQ+ clearance for adults with type 2 diabetes in 2025.

Sensor design is simultaneously improving. Manufacturers are competing on wear duration, insertion simplicity, physical size, warm-up time, calibration requirements and connectivity reliability. Longer sensor life can lower annual replacement frequency and make CGM more attractive to price-sensitive type 2 and OTC populations.

Medtronic’s Simplera Sync received FDA approval for use with MiniMed 780G in April 2025. The all-in-one disposable sensor expanded the company’s U.S. CGM portfolio and added another integrated sensor option to its automated insulin-delivery ecosystem. Later in 2025, Medtronic also received FDA clearance enabling MiniMed 780G integration with Abbott’s Instinct sensor and use of the system in type 2 diabetes, illustrating a broader strategic move toward cross-company sensor-pump interoperability.

The connected-injection category represents another important development. Not every insulin user wants or clinically requires a pump. Smart pens, connected pen caps and digital dose-recording technologies can capture insulin timing and dose history, reducing dependence on patient recall. When connected with CGM data, these technologies create a middle ground between traditional multiple daily injections and fully automated insulin delivery.

Algorithmic dosing support is moving beyond mealtime insulin. Dexcom received FDA clearance in November 2025 for Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults with type 2 diabetes using long-acting insulin. The system uses CGM information and logged insulin doses to generate personalized dosing recommendations under healthcare-provider direction. This expands the addressable market for connected therapeutic decision support beyond intensive insulin users.

Smartphone control is also becoming a competitive requirement rather than an optional convenience. Manufacturers are increasingly designing pumps and sensors around mobile-device compatibility, remote software upgrades and application-driven user experiences. Tandem began rolling out Android mobile control for Tandem Mobi during 2025 and expanded CGM interoperability across its portfolio.

Artificial intelligence and predictive analytics will provide an additional competitive layer. The commercial opportunity is not merely to collect more glucose data but to prioritize clinically meaningful patterns. Future systems are expected to identify recurring nocturnal hypoglycemia, post-meal excursions, missed medication patterns or deteriorating glucose control before these patterns become clinically costly.

Innovation, however, increases software and cybersecurity responsibility. Connected diabetes systems can directly influence therapeutic decisions, meaning manufacturers must manage software validation, mobile operating-system updates, wireless communication reliability, interoperability and human factors with the same rigor as physical device performance. Product recalls associated with software or dosing functionality demonstrate why reliability and post-market surveillance are likely to become more important competitive differentiators as automation expands.

 

Segmentation Insights

The U.S. Connected Diabetes Care Devices Market is segmented on the basis of product type, application, connectivity and data integration, end user, and distribution channel.

 

By Product Type

Continuous Glucose Monitoring Systems

Continuous glucose monitoring systems represent the largest product segment in the connected diabetes care market and are expected to remain the most important revenue pool through 2035. The segment includes sensors, transmitters where required, receivers, smartphone-connected platforms, professional CGMs and implantable CGM technologies.

Recurring sensor replacement gives CGM a structurally attractive revenue profile. The category is also expanding into non-insulin-treated type 2 diabetes, OTC metabolic monitoring and integration with multiple insulin-delivery platforms. Abbott and Dexcom are the largest commercial forces, while Medtronic, Senseonics and associated partners provide additional competitive options.

Connected Insulin Pumps and Automated Insulin Delivery Systems

Connected insulin pumps and AID systems are expected to be one of the fastest-growing product categories. This segment includes conventional durable pumps, patch pumps, automated dosing controllers and related infusion or pod consumables.

The key competitive shift is from insulin delivery to insulin automation. Insulet, Tandem, Medtronic, Beta Bionics and Sequel Med Tech are positioned within this evolving category. Type 2 indications considerably expand the long-term market beyond the traditional type 1 pump population.

Connected Blood Glucose Meters

Connected BGMs remain relevant despite rapid CGM penetration. Bluetooth-enabled meters provide relatively inexpensive connectivity, require limited training and fit populations that do not need continuous sensing. They remain important in Medicare, primary care, lower-frequency monitoring and cost-sensitive populations.

The segment is more mature and price-sensitive than CGM, but connectivity to mobile applications and cloud platforms can preserve clinical utility. LifeScan, Roche Diabetes Care, Ascensia, AgaMatrix, Trividia and other suppliers compete in this category.

Smart Insulin Pens and Connected Injection Devices

Smart pens and connected injection technologies address insulin users who remain on multiple daily injections. These systems record dose timing, improve dose-history visibility and can support insulin calculations when paired with glucose data.

Their long-term opportunity is particularly attractive in type 2 diabetes because the MDI population substantially exceeds the current pump population. Integration with CGM can transform a connected pen from a dose recorder into part of a broader decision-support ecosystem.

Device-Linked Software, Controllers and Data Hubs

This subsegment includes dedicated controllers, device receivers and software layers whose economic value is directly tied to connected diabetes hardware. While standalone software revenue is excluded from the core device estimate, integrated software is increasingly critical to differentiation. Manufacturers that own both the device and longitudinal data experience can increase retention, simplify remote monitoring and build stronger ecosystem switching costs.

 

By Application

Continuous Glucose Monitoring

Glucose monitoring remains the largest application. The market is transitioning from episodic measurements toward continuous glucose visibility. CGM is increasingly used not only to avoid severe highs and lows but also to understand time in range, glucose variability, overnight patterns and treatment response.

Automated Insulin Delivery

Automated insulin delivery represents the highest-value therapeutic application because it combines sensing, algorithms and insulin administration. Its addressable population is expanding as FDA-cleared systems move into type 2 diabetes. Increased competition should also encourage simpler form factors and broader payer coverage.

Connected Multiple Daily Injection Management

This application combines CGM or connected BGM data with smart pens, dose calculators and insulin-recording tools. It targets people requiring insulin but unwilling or unable to use pumps. The segment can become especially important in primary care because it offers greater treatment intelligence without requiring full pump adoption.

Remote Diabetes Management

Remote management includes connected-device data sharing with endocrinologists, primary-care physicians, diabetes educators and other care teams. It is becoming increasingly important as diabetes care combines in-person visits with remote review. The ability to identify patients requiring intervention rather than manually reviewing every patient dataset can improve clinician productivity.

Metabolic and Preventive Glucose Monitoring

OTC CGM has created a new application category around non-insulin-treated diabetes, prediabetes and metabolic awareness. The commercial ceiling is potentially large given the 115.2 million U.S. adults estimated to have prediabetes, although long-term utilization will depend on evidence, affordability, consumer retention and the ability to translate glucose data into clinically meaningful behavior.

 

By Connectivity and Data Integration

Bluetooth-Connected Devices

Bluetooth remains the dominant connectivity pathway for pumps, CGMs, BGMs and smart pens because it allows direct communication with smartphones and nearby controllers while maintaining relatively low energy requirements. Continued smartphone dependence means operating-system compatibility and app reliability are critical product considerations.

NFC-Enabled Devices

Near-field communication remains relevant in selected glucose-monitoring systems and provides low-friction data transfer. Its role is gradually being supplemented by continuous Bluetooth connectivity as patients increasingly expect real-time alarms and background synchronization.

Cloud-Connected Platforms

Cloud connectivity allows glucose and insulin information to move beyond the patient device into clinician dashboards, caregiver portals and remote-support systems. This architecture is becoming increasingly important for population management and longitudinal analytics.

Interoperable iCGM, ACE Pump and Automated Dosing Ecosystems

Interoperability represents one of the highest-value connectivity architectures. Rather than forcing a patient into a single closed manufacturer ecosystem, interoperable configurations allow compatible sensors, pumps and algorithms to communicate within regulated frameworks. The commercial importance of this architecture is increasing as pump companies offer multiple CGM options and sensor manufacturers seek integration across insulin-delivery platforms.

Multi-Protocol Connected Ecosystems

Premium platforms increasingly combine Bluetooth, cloud connectivity, smartphone applications, remote data sharing and firmware or software updates. These multi-protocol ecosystems can create stronger patient retention because replacing one component may disrupt established workflows and data histories.

 

By End User

Homecare and Individual Patients

Home use dominates the connected diabetes care market because glucose monitoring and insulin administration occur primarily outside institutional settings. Patient usability therefore has direct commercial importance. Smaller sensors, longer wear duration, simplified insertion, smartphone control and reduced alarm burden can influence adherence and product loyalty.

Hospitals and Health Systems

Hospitals are strategically important for initial diagnosis, inpatient glucose management, diabetes complications and discharge planning. Large health systems can also influence outpatient technology through endocrinology networks and formularies. Their purchasing decisions increasingly consider whether device data can integrate with broader clinical workflows.

Endocrinology and Diabetes Specialty Clinics

Specialty practices remain crucial because they manage complex type 1 diabetes, pump initiation, AID optimization and patients with difficult glycemic control. These clinics influence technology selection and often determine which connected systems achieve early clinical penetration.

Primary Care Practices

Primary care represents one of the most important future growth channels. Because most people with type 2 diabetes are managed outside endocrinology, expansion into this setting is essential for connected technology to move from specialist adoption to mass-market clinical use. Simplified prescription and onboarding processes will be necessary.

Remote Care and Diabetes Management Providers

Remote diabetes management companies use connected devices to create continuous relationships with patients. Their value proposition depends on data visibility between encounters. Device companies that provide standardized data access and reliable remote patient-sharing functionality are therefore more attractive to these organizations.

 

By Distribution Channel

Retail and Specialty Pharmacies

The pharmacy channel is becoming increasingly important for CGM, disposable patch pumps and other recurring diabetes supplies. Patients are accustomed to obtaining diabetes medications from pharmacies, and aligning device fulfillment with pharmaceutical workflows can reduce friction.

Durable Medical Equipment Suppliers

DME suppliers remain central to Medicare and many commercial-insurance pathways, particularly for durable pumps and CGM. They provide insurance verification, recurring supply fulfillment and documentation support. Manufacturers must therefore manage DME relationships alongside direct physician marketing.

Direct-to-Consumer and Manufacturer Fulfillment

Direct fulfillment is becoming more relevant as connected devices become easier to prescribe and consumer awareness rises. OTC CGM has expanded this route by allowing qualifying products to reach users without the traditional prescription workflow.

Hospital and Clinic Procurement

Clinical organizations procure professional glucose-monitoring systems, demonstration equipment and selected diabetes technologies. Although smaller by retail volume, these channels can materially influence patient conversion and brand selection.

E-Commerce and Digital Pharmacy Channels

Digital pharmacy models are becoming increasingly important for recurring consumables. The strongest platforms combine electronic prescriptions, insurance adjudication, automated shipment reminders and customer support. Over the forecast period, distribution efficiency will increasingly affect customer acquisition cost and retention.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Connected Diabetes Care Devices Market is geographically segmented into the South, West, Northeast and Midwest. Regional demand is influenced by diabetes prevalence, population size, age structure, insurance coverage, endocrinologist availability, health-system concentration, rural access, pharmacy infrastructure and digital-health adoption.

The South is estimated to represent the largest market at approximately USD 3.52 billion in 2025, followed by the West at USD 2.74 billion, Northeast at USD 2.22 billion and Midwest at USD 1.87 billion. The West is expected to record the fastest growth rate through 2035, while the South should retain the largest absolute revenue pool.

Geographic opportunity cannot be evaluated purely through disease prevalence. Regions with the highest diabetes burden do not always have the highest premium-device penetration because adoption is also affected by insurance mix, household income, provider access and specialty-care capacity. Connected technology may therefore create two different opportunities: premium automated systems in sophisticated metropolitan markets and scalable remote-monitoring solutions in medically underserved areas.

South

The South is estimated at USD 3.52 billion in 2025 and could reach approximately USD 12.55 billion by 2035. It includes Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia and West Virginia.

The region combines the country’s largest diabetes burden with several of its fastest-growing population centers. CDC analysis of rural and urban disparities found particularly elevated rural diabetes prevalence across multiple Southeastern states; rural prevalence reached 21.3% in North Carolina in the evaluated dataset, while urban prevalence reached 15.5% in West Virginia.

Texas is the most strategically important connected-diabetes market in the South because of its population scale, large commercial-insurance market, major provider networks in Houston, Dallas–Fort Worth, Austin and San Antonio, and high diabetes burden. The state is attractive across CGM, patch pumps, connected BGMs and remote diabetes management.

Florida is especially important for Medicare-oriented connected diabetes care because of its large older population. CGM, insulin-delivery systems and home monitoring technologies have strong potential where reimbursement aligns with eligibility requirements.

North Carolina, Georgia, Tennessee and Virginia provide substantial growth opportunities through expanding metropolitan markets, academic health systems and increasingly sophisticated diabetes programs. At the same time, rural populations create a strong use case for remotely connected devices because patients may live far from endocrinology specialists.

Alabama, Mississippi, Louisiana, Kentucky, West Virginia, Arkansas and Oklahoma represent high-need markets where affordability and access are particularly important. Premium diabetes technology can produce clinical value, but manufacturers must address coverage barriers, digital literacy, provider availability and distribution logistics.

The South’s long-term growth will be driven by the intersection of high disease burden and increased technology access. Manufacturers capable of pairing pharmacy distribution with payer-support services, simple onboarding and remote clinical education should have an advantage.

West

The West is estimated at USD 2.74 billion in 2025 and could reach approximately USD 10.80 billion by 2035, making it the fastest-growing region. It includes Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington and Wyoming.

California is by far the largest connected diabetes device market in the region. Its significance extends beyond patient volume because the state combines major academic medical centers, technology-oriented consumers, venture-backed digital health companies, large integrated health systems and a strong medical-device innovation ecosystem. California is particularly influential for CGM, connected pumps, smartphone-centered diabetes platforms and digitally enabled care models.

Arizona and Nevada benefit from population growth and aging demographics. Both provide attractive opportunities for CGM and insulin-delivery systems, particularly as older patients increasingly become eligible for connected monitoring through Medicare pathways.

Washington, Oregon, Colorado and Utah have strong integrated-care environments and relatively high acceptance of digital health. These states are likely to be early adopters of interoperable systems, remote monitoring and consumer-oriented glucose sensing.

The West also demonstrates why disease prevalence alone does not determine device-market value. CDC analysis found rural diabetes prevalence as low as 8.4% in Colorado and urban prevalence as low as 6.9%, yet the state remains commercially attractive because of health-system sophistication, insurance coverage and connected-care readiness.

New Mexico, Idaho, Montana, Wyoming and Alaska provide a different opportunity. Lower population density and long travel distances make remote data sharing especially valuable. Connected diabetes devices can reduce the information gap between specialist visits, but logistical support and broadband or smartphone access can influence adoption.

Hawaii represents a smaller revenue market but remains relevant for remote monitoring because geography creates natural constraints on specialty-care access.

The West is expected to gain market share through 2035 as diabetes technology becomes more software-driven, interoperable and consumer accessible.

Northeast

The Northeast is estimated at approximately USD 2.22 billion in 2025 and could reach about USD 7.80 billion by 2035. The region includes Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York and Pennsylvania.

The Northeast has lower population growth than the South and West but maintains high connected-device value per eligible patient because of specialist density, strong commercial insurance markets and major academic health systems.

New York represents the largest state market in the Northeast. The New York metropolitan area supports significant endocrinology capacity and a large, diverse diabetes population. Large integrated delivery networks also provide opportunities for enterprise-level diabetes data integration.

Pennsylvania and New Jersey provide substantial patient pools and mature provider systems. CGM adoption, connected insulin delivery and pharmacy-based distribution are important commercial opportunities across both states.

Massachusetts is disproportionately influential relative to its population because of its academic medicine, medical-device innovation, clinical research infrastructure and technology-oriented care models. Novel diabetes technologies can gain early clinical credibility through leading Boston-area institutions.

Connecticut, Rhode Island, New Hampshire, Maine and Vermont are smaller absolute markets but maintain comparatively sophisticated care environments. Northern New England also contains rural populations where remote monitoring can improve the continuity of diabetes management.

The Northeast’s competitive environment is likely to favor products with strong clinical evidence and interoperability. Health systems in the region increasingly evaluate whether new technologies fit broader data-governance, cybersecurity and population-health strategies rather than assessing the device in isolation.

Midwest

The Midwest is estimated at USD 1.87 billion in 2025 and could reach approximately USD 6.55 billion by 2035. The region includes Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota and Wisconsin.

The Midwest offers a balanced connected diabetes market: major academic and metropolitan health systems support advanced technology adoption, while large rural areas create demand for remote monitoring and simplified home-care technologies.

Illinois, Ohio and Michigan represent the largest patient and provider markets. Chicago, Cleveland, Columbus, Cincinnati, Detroit and other major metropolitan areas support substantial endocrinology networks and commercially insured populations.

Minnesota is strategically important because of its deep medical-device ecosystem and history in diabetes technology. The state remains relevant to product development, clinical expertise and connected-care innovation.

Indiana, Wisconsin, Missouri and Iowa provide durable demand across CGM, connected glucose meters and insulin-delivery systems. Manufacturers that combine competitive contracting with strong distributor and pharmacy support can build significant share.

Kansas, Nebraska, North Dakota and South Dakota are smaller markets but demonstrate the value proposition of connectivity in rural diabetes management. Remote access to glucose information can help bridge the distance between patients and diabetes specialists.

The Midwest and South also have comparatively high obesity prevalence. CDC estimates for 2024 placed adult obesity prevalence at approximately 35.9% in the Midwest and 34.5% in the South, compared with 30.2% in the West and 30.3% in the Northeast. The epidemiologic pattern reinforces continued long-term diabetes-management demand.

 

Key Market Players

The U.S. Connected Diabetes Care Devices competitive landscape is increasingly concentrated around integrated technology ecosystems, although specialist companies continue to create meaningful innovation in CGM, automated insulin delivery, smart injection, connected meters and diabetes data management.

Some of the major and strategically relevant players operating across the U.S. connected diabetes care ecosystem include Abbott Diabetes Care, Dexcom, Medtronic Diabetes, Insulet Corporation, Tandem Diabetes Care, Beta Bionics, Sequel Med Tech, Senseonics Holdings, Ascensia Diabetes Care, Roche Diabetes Care, LifeScan, embecta, Eli Lilly and Company, Novo Nordisk, Glooko, Tidepool, DarioHealth, Teladoc Health/Livongo, Omada Health, AgaMatrix, Trividia Health, i-SENS, Prodigy Diabetes Care, and Ypsomed.

Abbott and Dexcom are the strongest competitors in connected glucose sensing. Abbott’s global CGM sales reached approximately USD 7.6 billion during 2025, while Dexcom generated approximately USD 4.66 billion worldwide and USD 3.33 billion in the United States. Their competition is increasingly centered on wear duration, form factor, reimbursement, OTC access, pharmacy distribution and integration with insulin-delivery systems rather than glucose accuracy alone.

Insulet has established a powerful recurring-revenue model around the tubeless Omnipod platform. Its U.S. Omnipod revenue reached approximately USD 1.9 billion in 2025, increasing 27.2% year over year. Expansion of automated insulin delivery into type 2 diabetes strengthens the company’s addressable market.

Tandem competes through t:slim X2, Tandem Mobi and Control-IQ+ and generated approximately USD 706.9 million in U.S. sales during 2025. Its growing integration with multiple CGM systems and transition toward broader distribution models illustrate how insulin-pump competition is shifting toward ecosystem flexibility.

Medtronic remains a strategically important integrated competitor through MiniMed 780G, CGM technologies, SmartGuard algorithms and connected injection capabilities. The addition of Simplera Sync and integration with Abbott’s Instinct sensor demonstrate an increasingly open partnership strategy.

Beta Bionics and Sequel Med Tech increase competitive pressure in automated insulin delivery, while Senseonics and Ascensia participate in implantable CGM. Roche, LifeScan, AgaMatrix, Trividia and i-SENS remain relevant to connected BGM, while embecta, pharmaceutical manufacturers and smart-injection developers influence the connected MDI opportunity.

The competitive hierarchy through 2035 will depend on more than FDA clearance. Companies will compete on payer access, pharmacy placement, sensor and consumable economics, patient retention, clinician workflow, mobile usability, customer service, interoperability and real-world outcomes. As hardware differences narrow, ecosystem performance will increasingly determine market share.

 

Recent Developments

Recent U.S. developments show that connected diabetes care is transitioning from specialist technology toward broader disease-management infrastructure.

In March 2024, the FDA cleared Dexcom Stelo as the first over-the-counter CGM in the United States for adults who do not use insulin. The regulatory pathway significantly widened the commercially addressable CGM population beyond traditional prescription users.

In August 2024, the FDA expanded Insulet SmartAdjust technology for adults with type 2 diabetes, creating the first automated insulin-dosing technology cleared for this population. The decision was based in part on a study involving 289 adults with insulin-treated type 2 diabetes.

In February 2025, Tandem Diabetes Care announced FDA clearance of Control-IQ+ for adults with type 2 diabetes. The expanded indication moved another leading automated insulin-delivery platform beyond the historic type 1 market.

In April 2025, Medtronic received FDA approval for Simplera Sync for use with MiniMed 780G, giving its automated insulin-delivery platform an additional all-in-one CGM sensor option.

During 2025, Dexcom launched the G7 15 Day CGM in the United States and obtained FDA clearance for Smart Basal, extending the role of connected sensing from glucose observation toward basal-insulin dose optimization.

Medtronic subsequently expanded MiniMed 780G interoperability and type 2 positioning, including integration with Abbott sensor technology. Such cross-company partnerships indicate that future diabetes ecosystems may become less vertically closed as manufacturers compete to give patients and clinicians greater component choice.

Safety and reliability remain critical. As insulin-delivery systems become more software dependent, software errors, connectivity problems and hardware defects can directly affect dosing. Recent FDA diabetes-device recalls illustrate why manufacturers must invest heavily in software quality, cybersecurity, manufacturing controls and post-market surveillance.

A significant post-base-year development occurred in June 2026, when FDA OTC clearance of Dexcom Stelo was expanded to individuals aged two years and older who do not use insulin. This indicates that the addressable connected-glucose market could continue expanding beyond conventional diabetes treatment into family-managed and preventive metabolic monitoring.

 

Conclusion

The U.S. Connected Diabetes Care Devices Market Size & Share is positioned to expand from approximately USD 10.35 billion in 2025 to USD 37.70 billion by 2035, representing a CAGR of 13.80% during 2026–2035. Historical market value is estimated to have increased from USD 4.24 billion in 2021 to USD 8.18 billion in 2024 as CGM, connected insulin delivery and recurring device-consumable ecosystems scaled rapidly.

The strongest growth engine will remain continuous glucose monitoring, but the most strategically important shift is the movement from monitoring to automated and algorithm-supported therapy. Type 2 diabetes represents the critical expansion frontier. FDA clearances for automated insulin delivery in type 2 diabetes fundamentally increase the potential customer pool for technologies that were previously concentrated in type 1 disease.

The competitive model is also changing. A successful diabetes-device company can no longer rely solely on sensor accuracy, pump mechanics or meter pricing. Manufacturers increasingly need an integrated proposition consisting of reliable hardware, recurring consumables, mobile connectivity, algorithm performance, pharmacy or DME access, payer support, clinician-friendly analytics and data interoperability.

CGM will remain the largest product category, while automated insulin delivery, smart injection and connected type 2 management are expected to produce disproportionate incremental growth. Connected BGMs will remain clinically relevant but become more price-sensitive as CGM access expands.

Regionally, the South will remain the largest revenue market, supported by population size and high diabetes burden. The West should record the fastest growth, driven by technology adoption, digital-care infrastructure and large commercial markets such as California. The Northeast will remain an evidence-intensive premium market, while the Midwest will provide a durable combination of metropolitan technology adoption and rural remote-management opportunity.

For manufacturers, investors, distributors and healthcare organizations evaluating this market, the key strategic question is no longer whether diabetes care will become more connected. That transition is already established. The more important questions are which patient populations will convert next, how quickly CGM and automated insulin delivery penetrate type 2 diabetes, which reimbursement channels reduce adoption friction, and which device ecosystems become sufficiently interoperable and clinically useful to retain patients over multiple replacement cycles.

The strongest companies through 2035 will be those able to turn diabetes devices from isolated pieces of hardware into dependable longitudinal care platforms—while simultaneously delivering measurable clinical benefit, manageable patient economics, simple provider workflows and the level of reliability required for increasingly automated therapy.

 

TABLE OF CONTENT

1. U.S. Connected Diabetes Care Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Continuous Glucose Monitoring Device Manufacturers
1.6.2. Connected Insulin Delivery and Automated Insulin Delivery Manufacturers
1.6.3. Smart Insulin Pen and Connected Injection Device Manufacturers
1.6.4. Connected Blood Glucose Meter Manufacturers
1.6.5. Diabetes Data Management and Device Connectivity Providers
1.6.6. Endocrinology Practices, Diabetes Centers and Primary Care Providers
1.6.7. Pharmacies, Durable Medical Equipment Suppliers and Distributors
1.6.8. Commercial Payers, Medicare, Medicaid and Pharmacy Benefit Managers
1.6.9. FDA, CMS and Clinical Decision-Makers
What this section provides: This section establishes the U.S. Connected Diabetes Care Devices Market boundary, study scope, methodology, assumptions and stakeholder ecosystem, enabling clients to understand how connected glucose monitoring, insulin delivery, smart injection and device-linked data technologies are measured and validated.

2. U.S. Connected Diabetes Care Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size Evolution, 2021–2035
2.8. High-Growth Opportunity Areas
2.9. Connected Diabetes Technology Adoption Outlook
2.10. Type 1 vs. Type 2 Diabetes Technology Opportunity
2.11. Key Strategic Findings for Manufacturers, Investors and Providers
What this section provides: This section gives decision-makers an executive view of market size, historical expansion, forecast direction, adoption trends, competitive intensity and priority opportunities across connected diabetes monitoring and insulin-management technologies.

3. U.S. Connected Diabetes Care Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Diabetes and Prediabetes Burden
3.1.2. Rapid Expansion of Continuous Glucose Monitoring Adoption
3.1.3. Growing Adoption of Automated Insulin Delivery Systems
3.1.4. Expansion of Connected Diabetes Technologies into Type 2 Diabetes
3.1.5. Medicare and Commercial Payer Coverage Expansion
3.1.6. Shift Toward Home-Based and Remote Diabetes Management
3.1.7. Rising Patient Preference for Smartphone-Connected Diabetes Devices
3.1.8. Growing Clinical Importance of Time-in-Range and Continuous Data
3.2. Restraints and Their Impact Analysis
3.2.1. High Recurring Cost of CGM Sensors, Pumps and Consumables
3.2.2. Payer Coverage Variability and Prior Authorization Barriers
3.2.3. Device Compatibility and Interoperability Limitations
3.2.4. Cybersecurity and Patient Data Privacy Concerns
3.2.5. Device Recall, Software Reliability and Dosing Safety Risks
3.2.6. Digital Literacy and Technology Adoption Barriers
3.3. Opportunities and Their Impact Analysis
3.3.1. CGM Expansion into Non-Insulin-Treated Type 2 Diabetes
3.3.2. Over-the-Counter Continuous Glucose Monitoring
3.3.3. Automated Insulin Delivery for Type 2 Diabetes
3.3.4. Smart Insulin Pens and Connected Multiple Daily Injection Management
3.3.5. Longer-Wear and Next-Generation CGM Sensors
3.3.6. Interoperable CGM-Pump-Algorithm Ecosystems
3.3.7. Primary Care-Based Connected Diabetes Management
3.3.8. Remote Patient Monitoring and Population-Level Diabetes Management
3.4. Challenges and Their Impact Analysis
3.4.1. Patient Retention and Device Discontinuation
3.4.2. Alarm Fatigue and User Experience Complexity
3.4.3. Integration with Electronic Health Records
3.4.4. Provider Workflow and Data Overload
3.4.5. Affordability Across Underserved Populations
3.4.6. Software Update and Mobile Operating System Compatibility
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Patient Lifetime Value and Recurring Consumables Economics
3.8. Payer, Pharmacy and DME Procurement Behavior Analysis
3.9. Connected Diabetes Device Adoption Curve Analysis
What this section provides: This section explains the clinical, commercial, reimbursement, technological and behavioral factors shaping connected diabetes device demand and helps clients assess growth catalysts, adoption barriers, execution risks and emerging opportunities.

4. U.S. Connected Diabetes Care Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers and Payers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization and Connected Diabetes Care
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. Continuous Glucose Monitoring Regulatory Pathways
4.7.2. Integrated Continuous Glucose Monitoring Framework
4.7.3. Automated Insulin Dosing System Regulation
4.7.4. Alternate Controller Enabled Insulin Pump Framework
4.7.5. Connected Blood Glucose Meter and Smart Injection Device Regulation
4.8. CMS Reimbursement and Coverage Landscape
4.8.1. Medicare CGM Coverage
4.8.2. Medicare Insulin Pump Coverage
4.8.3. Pharmacy Benefit vs. Durable Medical Equipment Coverage
4.8.4. Commercial Insurance Coverage Dynamics
4.8.5. Medicaid Access Considerations
4.9. Pharmacy, DME and Distribution Ecosystem
4.10. Device Interoperability and Data Integration Landscape
4.11. Cybersecurity and Connected Medical Device Compliance
4.12. Import/Export Restrictions & Tariff Impact
4.13. Government Initiatives and Diabetes Public Health Programs
4.14. Impact of Escalating Geopolitical and Supply Chain Tensions
4.15. Payer Formulary and Value Assessment Decision Framework
What this section provides: This section provides a comprehensive view of regulation, reimbursement, pricing, supply chains, interoperability, cybersecurity, payer access and broader environmental factors affecting the commercialization of connected diabetes care technologies in the United States.

5. U.S. Connected Diabetes Care Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Continuous Glucose Monitoring Systems
5.1.2.1. Real-Time Continuous Glucose Monitoring Systems
5.1.2.2. Intermittently Scanned Continuous Glucose Monitoring Systems
5.1.2.3. Implantable Continuous Glucose Monitoring Systems
5.1.2.4. Over-the-Counter Continuous Glucose Monitoring Systems
5.1.2.5. Professional Continuous Glucose Monitoring Systems
5.1.3. Connected Insulin Pumps & Automated Insulin Delivery Systems
5.1.3.1. Durable Connected Insulin Pumps
5.1.3.2. Tubeless and Patch Insulin Pumps
5.1.3.3. Hybrid Closed-Loop Systems
5.1.3.4. Automated Insulin Delivery Systems
5.1.3.5. Pump Controllers and Associated Consumables
5.1.4. Connected Blood Glucose Monitoring Systems
5.1.4.1. Bluetooth-Enabled Blood Glucose Meters
5.1.4.2. Smartphone-Connected Glucose Meters
5.1.4.3. Cloud-Connected Blood Glucose Monitoring Systems
5.1.4.4. Multi-User and Remote Monitoring Glucose Meters
5.1.5. Smart Insulin Pens & Connected Injection Devices
5.1.5.1. Reusable Smart Insulin Pens
5.1.5.2. Connected Disposable Insulin Pens
5.1.5.3. Smart Pen Caps and Add-On Connectivity Devices
5.1.5.4. Dose Tracking and Dose Capture Devices
5.1.6. Device-Linked Software, Controllers & Data Hubs
5.1.6.1. Dedicated Device Receivers and Controllers
5.1.6.2. Smartphone-Based Device Control Applications
5.1.6.3. Connected Diabetes Data Platforms
5.1.6.4. Clinician-Facing Device Analytics Interfaces
What this section provides: This section identifies which connected diabetes device categories will generate the greatest revenue contribution, recurring consumable demand and incremental growth through 2035.

6. U.S. Connected Diabetes Care Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Continuous Glucose Monitoring
6.1.2.1. Type 1 Diabetes Glucose Monitoring
6.1.2.2. Insulin-Treated Type 2 Diabetes Monitoring
6.1.2.3. Non-Insulin-Treated Type 2 Diabetes Monitoring
6.1.2.4. Hypoglycemia Detection and Prevention
6.1.3. Automated Insulin Delivery
6.1.3.1. Type 1 Diabetes Automated Insulin Delivery
6.1.3.2. Type 2 Diabetes Automated Insulin Delivery
6.1.3.3. Hybrid Closed-Loop Therapy
6.1.3.4. Algorithm-Assisted Insulin Adjustment
6.1.4. Connected Multiple Daily Injection Management
6.1.4.1. Smart Insulin Dose Recording
6.1.4.2. Bolus Calculation and Decision Support
6.1.4.3. Basal Insulin Optimization
6.1.4.4. Medication Adherence Monitoring
6.1.5. Remote Diabetes Management
6.1.5.1. Remote Patient Monitoring
6.1.5.2. Clinician Glucose Data Review
6.1.5.3. Caregiver Data Sharing
6.1.5.4. Population Health Diabetes Management
6.1.6. Metabolic & Preventive Glucose Monitoring
6.1.6.1. Prediabetes Monitoring
6.1.6.2. OTC Glucose Monitoring
6.1.6.3. Lifestyle and Metabolic Response Monitoring
6.1.6.4. Preventive Risk Management
What this section provides: This section helps clients understand connected diabetes device demand by therapeutic and monitoring application and identifies the clinical use cases positioned for the fastest adoption through 2035.

7. U.S. Connected Diabetes Care Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Homecare & Individual Patients
7.1.2.1. Type 1 Diabetes Patients
7.1.2.2. Insulin-Treated Type 2 Diabetes Patients
7.1.2.3. Non-Insulin-Treated Type 2 Diabetes Patients
7.1.2.4. Prediabetes and OTC CGM Users
7.1.3. Hospitals & Health Systems
7.1.3.1. Academic Medical Centers
7.1.3.2. Community Hospitals
7.1.3.3. Integrated Delivery Networks
7.1.3.4. Hospital-Based Diabetes Programs
7.1.4. Endocrinology & Diabetes Specialty Clinics
7.1.4.1. Endocrinology Practices
7.1.4.2. Diabetes Centers
7.1.4.3. Certified Diabetes Care and Education Programs
7.1.4.4. Pediatric Diabetes Centers
7.1.5. Primary Care Practices
7.1.5.1. Independent Primary Care Practices
7.1.5.2. Health System-Affiliated Primary Care
7.1.5.3. Accountable Care Organizations
7.1.5.4. Community Health Centers
7.1.6. Remote Care & Diabetes Management Providers
7.1.6.1. Remote Patient Monitoring Providers
7.1.6.2. Virtual Diabetes Clinics
7.1.6.3. Digital Chronic Care Providers
7.1.6.4. Employer-Sponsored Diabetes Management Programs
What this section provides: This section identifies which patient groups, provider settings and care models are expected to drive connected diabetes device initiation, recurring utilization and longitudinal data-management demand.

8. U.S. Connected Diabetes Care Devices Market – By Connectivity & Data Integration

8.1. Overview
8.1.1. Segment Share Analysis, By Connectivity & Data Integration, 2025 & 2035 (%)
8.1.2. Bluetooth-Connected Devices
8.1.2.1. Bluetooth CGM Systems
8.1.2.2. Bluetooth Insulin Pumps
8.1.2.3. Bluetooth Blood Glucose Meters
8.1.2.4. Bluetooth Smart Insulin Pens
8.1.3. NFC-Enabled Devices
8.1.3.1. NFC Glucose Sensors
8.1.3.2. Smartphone-Scanned Glucose Devices
8.1.3.3. Hybrid NFC-Bluetooth Systems
8.1.4. Cloud-Connected Platforms
8.1.4.1. Patient Cloud Data Platforms
8.1.4.2. Clinician Cloud Dashboards
8.1.4.3. Caregiver Data-Sharing Platforms
8.1.4.4. Remote Monitoring Data Infrastructure
8.1.5. Interoperable Diabetes Device Ecosystems
8.1.5.1. iCGM-Enabled Ecosystems
8.1.5.2. ACE Insulin Pump Ecosystems
8.1.5.3. Automated Insulin Dosing Interoperability
8.1.5.4. Cross-Manufacturer CGM-Pump Integration
8.1.6. Multi-Protocol Connected Ecosystems
8.1.6.1. Smartphone-Controlled Systems
8.1.6.2. Cloud-Synchronized Device Ecosystems
8.1.6.3. EHR-Integrated Diabetes Device Platforms
8.1.6.4. AI-Assisted Connected Diabetes Platforms
What this section provides: This section assesses the connectivity architectures that determine interoperability, user experience, remote monitoring capability, ecosystem flexibility and long-term competitive differentiation in connected diabetes care.

9. U.S. Connected Diabetes Care Devices Market – By Distribution Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2035 (%)
9.1.2. Retail & Specialty Pharmacies
9.1.2.1. National Retail Pharmacy Chains
9.1.2.2. Specialty Pharmacies
9.1.2.3. Independent Pharmacies
9.1.2.4. Health System Pharmacies
9.1.3. Durable Medical Equipment Suppliers
9.1.3.1. National DME Suppliers
9.1.3.2. Regional DME Suppliers
9.1.3.3. Medicare-Focused DME Suppliers
9.1.4. Direct-to-Consumer & Manufacturer Fulfillment
9.1.4.1. Manufacturer Direct Fulfillment
9.1.4.2. OTC CGM Direct Sales
9.1.4.3. Subscription and Recurring Supply Models
9.1.5. Hospital & Clinic Procurement
9.1.5.1. Hospital Procurement
9.1.5.2. Endocrinology Clinic Procurement
9.1.5.3. Diabetes Center Procurement
9.1.5.4. Professional CGM Procurement
9.1.6. E-Commerce & Digital Pharmacy Channels
9.1.6.1. Online Pharmacies
9.1.6.2. Digital Prescription Platforms
9.1.6.3. Online Diabetes Supply Retailers
9.1.6.4. Digital Health Platform Distribution
What this section provides: This section explains how connected diabetes devices and recurring consumables reach U.S. patients through pharmacy, DME, direct, institutional and digital distribution pathways and evaluates the channel shifts likely to influence market access through 2035.

10. U.S. Connected Diabetes Care Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Diabetes Prevalence and Addressable Patient Analysis
10.1.4. Regional CGM and Automated Insulin Delivery Adoption Analysis
10.1.5. Regional Reimbursement, Pharmacy and DME Dynamics
10.1.6. Regional Endocrinology and Diabetes Care Infrastructure Analysis
10.1.7. Regional Connected Care and Remote Monitoring Readiness

10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region Connected Diabetes Device Key Manufacturers and Commercial Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Connected Diabetes Device Key Manufacturers and Commercial Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)

10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region Connected Diabetes Device Key Manufacturers and Commercial Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Connected Diabetes Device Key Manufacturers and Commercial Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Connectivity & Data Integration, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
What this section provides: This section delivers detailed regional and state-level analysis of all 50 states, enabling clients to identify connected diabetes device adoption hotspots, high-burden diabetes markets, CGM and AID opportunities, payer-access differences, distribution priorities and state-level commercial opportunities.

11. U.S. Connected Diabetes Care Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.1.1. Overall Connected Diabetes Care Devices Market Share
11.1.2. Continuous Glucose Monitoring Competitive Share
11.1.3. Connected Insulin Delivery Competitive Share
11.1.4. Connected BGM and Smart Injection Competitive Positioning
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players
11.3. Competitive Benchmarking
11.3.1. Product Portfolio Breadth
11.3.2. U.S. Installed Patient Base
11.3.3. Connectivity & Interoperability
11.3.4. Regulatory Positioning
11.3.5. Reimbursement and Market Access
11.3.6. Distribution Channel Strength
11.3.7. Innovation Pipeline
11.4. Company Profiles
11.4.1. Abbott Diabetes Care
11.4.2. Dexcom, Inc.
11.4.3. Medtronic Diabetes
11.4.4. Insulet Corporation
11.4.5. Tandem Diabetes Care, Inc.
11.4.6. Beta Bionics, Inc.
11.4.7. Sequel Med Tech, LLC
11.4.8. Senseonics Holdings, Inc.
11.4.9. Ascensia Diabetes Care
11.4.10. Roche Diabetes Care
11.4.11. LifeScan, Inc.
11.4.12. embecta Corp.
11.4.13. Novo Nordisk A/S
11.4.14. Eli Lilly and Company
11.4.15. Ypsomed Holding AG
11.4.16. Glooko, Inc.
11.4.17. DarioHealth Corp.
11.4.18. Teladoc Health / Livongo
11.4.19. Omada Health, Inc.
11.4.20. Tidepool
11.4.21. AgaMatrix, Inc.
11.4.22. Trividia Health, Inc.
11.4.23. i-SENS, Inc.
11.4.24. Prodigy Diabetes Care, LLC
11.4.25. Modular Medical, Inc.
11.5. Company Profile Parameters
11.5.1. Company Overview
11.5.2. Connected Diabetes Device Portfolio
11.5.3. U.S. Market Strategy
11.5.4. Financial Positioning
11.5.5. Product and Clinical Pipeline
11.5.6. FDA Regulatory Updates
11.5.7. Reimbursement and Market Access Strategy
11.5.8. Partnerships and Interoperability Strategy
11.5.9. Recent Developments
11.5.10. Strategic Strengths and Competitive Risks
What this section provides: This section gives clients competitor benchmarking, market-share visibility, product and ecosystem positioning, interoperability intelligence, regulatory strategy and detailed profiles of major and emerging U.S. connected diabetes care companies.

12. U.S. Connected Diabetes Care Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Longer-Wear and Next-Generation CGM
12.2.2. OTC Continuous Glucose Monitoring
12.2.3. Automated Insulin Delivery for Type 2 Diabetes
12.2.4. Fully Closed-Loop Insulin Delivery
12.2.5. Smart Insulin Pens and Connected Injection Systems
12.2.6. CGM-Integrated Basal Insulin Optimization
12.2.7. Interoperable CGM-Pump-Algorithm Ecosystems
12.2.8. AI-Assisted Diabetes Management and Predictive Analytics
12.2.9. Implantable and Extended-Duration Glucose Sensors
12.2.10. Non-Invasive and Minimally Invasive Glucose Monitoring
12.3. Emerging Business Trends
12.3.1. Shift from Prescription CGM to Consumer-Accessible Monitoring
12.3.2. Pharmacy Channel Expansion
12.3.3. Subscription and Recurring Consumable Models
12.3.4. Device-as-a-Platform Business Models
12.3.5. Cross-Manufacturer Interoperability Partnerships
12.3.6. Diabetes Device and Pharmaceutical Convergence
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Technology Adoption Roadmap, 2026–2035
12.7. Connected Diabetes Device White-Space Analysis
12.8. Market Consolidation and M&A Outlook
What this section provides: This section prepares clients for future technology shifts, patient-pool expansion, competitive restructuring, investment opportunities and alternative connected diabetes device adoption scenarios through 2035.

13. U.S. Connected Diabetes Care Devices Market: Strategic Recommendations

13.1. Recommendations for Connected Diabetes Device Manufacturers
13.1.1. CGM Manufacturers
13.1.2. Insulin Pump and AID Manufacturers
13.1.3. Smart Insulin Pen Manufacturers
13.1.4. Connected BGM Manufacturers
13.1.5. Diabetes Data and Connectivity Providers
13.2. Recommendations for Hospitals, Endocrinology Clinics and Primary Care Networks
13.3. Recommendations for Commercial Payers and Healthcare Plans
13.4. Recommendations for Investors and Private Equity Firms
13.5. Recommendations for Pharmacies, DME Suppliers and Channel Partners
13.6. Recommendations for New Entrants and Startups
13.7. Go-to-Market Strategy Considerations
13.7.1. Type 1 Diabetes Market Entry Strategy
13.7.2. Type 2 Diabetes Expansion Strategy
13.7.3. Medicare Market Access Strategy
13.7.4. Commercial Payer Access Strategy
13.7.5. Pharmacy and DME Channel Strategy
13.8. Product Positioning and Portfolio Expansion Guidance
13.9. Interoperability and Partnership Strategy
13.10. State and Regional Commercial Prioritization
13.11. Pricing and Reimbursement Strategy
13.12. Patient Acquisition and Retention Strategy
What this section provides: This section converts the market intelligence into actionable recommendations for product positioning, patient expansion, payer access, distribution strategy, interoperability, investment prioritization and competitive differentiation.

14. U.S. Connected Diabetes Care Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Market Definition Limitation
14.4. Forecasting Limitation
14.5. Regulatory and Reimbursement Limitation
14.6. Legal Disclaimer
14.7. Third-Party Data Disclaimer
What this section provides: This section clarifies the report’s scope, market-sizing boundaries, forecasting assumptions, regulatory limitations, third-party data usage and legal conditions governing interpretation of the U.S. Connected Diabetes Care Devices Market report.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Connected Diabetes Care Devices Market: Market Definition and Scope
TABLE 3: U.S. Connected Diabetes Care Devices Market: Research Methodology Framework
TABLE 4: U.S. Connected Diabetes Care Devices Market: Key Assumptions
TABLE 5: U.S. Connected Diabetes Care Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Connected Diabetes Care Devices Market: Stakeholder Analysis
TABLE 7: U.S. Connected Diabetes Care Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Connected Diabetes Care Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Connected Diabetes Care Devices Market: Market Attractiveness Index
TABLE 10: U.S. Connected Diabetes Care Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Connected Diabetes Care Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Connected Diabetes Care Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Connected Diabetes Care Devices Market: High-Growth Opportunity Areas
TABLE 14: U.S. Connected Diabetes Care Devices Market: Type 1 vs. Type 2 Diabetes Technology Opportunity
TABLE 15: U.S. Connected Diabetes Care Devices Market: Drivers; Impact Analysis
TABLE 16: U.S. Connected Diabetes Care Devices Market: Restraints; Impact Analysis
TABLE 17: U.S. Connected Diabetes Care Devices Market: Opportunities; Impact Analysis
TABLE 18: U.S. Connected Diabetes Care Devices Market: Challenges; Impact Analysis
TABLE 19: U.S. Connected Diabetes Care Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 20: U.S. Connected Diabetes Care Devices Market: Clinical Workflow Economics Matrix
TABLE 21: U.S. Connected Diabetes Care Devices Market: Patient Lifetime Value and Recurring Consumables Economics
TABLE 22: U.S. Connected Diabetes Care Devices Market: Payer, Pharmacy and DME Procurement Behavior Matrix
TABLE 23: U.S. Connected Diabetes Care Devices Market: Connected Diabetes Device Adoption Curve Analysis
TABLE 24: U.S. Connected Diabetes Care Devices Market: PESTEL Analysis
TABLE 25: U.S. Connected Diabetes Care Devices Market: Porter’s Five Forces Analysis
TABLE 26: U.S. Connected Diabetes Care Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 27: U.S. Connected Diabetes Care Devices Market: Value Chain Analysis
TABLE 28: U.S. Connected Diabetes Care Devices Market: Supply Chain Analysis
TABLE 29: U.S. Connected Diabetes Care Devices Market: Digitalization and Connected Diabetes Care Impact
TABLE 30: U.S. Connected Diabetes Care Devices Market: Application & Innovation Landscape
TABLE 31: U.S. Connected Diabetes Care Devices Market: FDA Regulatory Framework Analysis
TABLE 32: U.S. Connected Diabetes Care Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 33: U.S. Connected Diabetes Care Devices Market: Pharmacy, DME and Distribution Ecosystem
TABLE 34: U.S. Connected Diabetes Care Devices Market: Device Interoperability and Data Integration Landscape
TABLE 35: U.S. Connected Diabetes Care Devices Market: Cybersecurity and Connected Medical Device Compliance
TABLE 36: U.S. Connected Diabetes Care Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 37: U.S. Connected Diabetes Care Devices Market: Government Initiatives and Diabetes Public Health Programs
TABLE 38: U.S. Connected Diabetes Care Devices Market: Impact of Escalating Geopolitical and Supply Chain Tensions
TABLE 39: U.S. Connected Diabetes Care Devices Market: Payer Formulary and Value Assessment Decision Framework
TABLE 40: U.S. Connected Diabetes Care Devices Market: Product Type Snapshot, 2025
TABLE 41: Segment Dashboard; Definition and Scope, by Product Type
TABLE 42: U.S. Connected Diabetes Care Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 43: U.S. Connected Diabetes Care Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 44: U.S. Connected Diabetes Care Devices Market: Continuous Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. Connected Diabetes Care Devices Market: Connected Insulin Pumps & Automated Insulin Delivery Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Connected Diabetes Care Devices Market: Connected Blood Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Connected Diabetes Care Devices Market: Smart Insulin Pens & Connected Injection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Connected Diabetes Care Devices Market: Device-Linked Software, Controllers & Data Hubs Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. Connected Diabetes Care Devices Market: Application Snapshot, 2025
TABLE 50: Segment Dashboard; Definition and Scope, by Application
TABLE 51: U.S. Connected Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 52: U.S. Connected Diabetes Care Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 53: U.S. Connected Diabetes Care Devices Market: Continuous Glucose Monitoring Application Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Connected Diabetes Care Devices Market: Automated Insulin Delivery Application Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Connected Diabetes Care Devices Market: Connected Multiple Daily Injection Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Connected Diabetes Care Devices Market: Remote Diabetes Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Connected Diabetes Care Devices Market: Metabolic & Preventive Glucose Monitoring Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Connected Diabetes Care Devices Market: End User Snapshot, 2025
TABLE 59: Segment Dashboard; Definition and Scope, by End User
TABLE 60: U.S. Connected Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 61: U.S. Connected Diabetes Care Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 62: U.S. Connected Diabetes Care Devices Market: Homecare & Individual Patients Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Connected Diabetes Care Devices Market: Hospitals & Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Connected Diabetes Care Devices Market: Endocrinology & Diabetes Specialty Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Connected Diabetes Care Devices Market: Primary Care Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Connected Diabetes Care Devices Market: Remote Care & Diabetes Management Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. Connected Diabetes Care Devices Market: Connectivity & Data Integration Snapshot, 2025
TABLE 68: Segment Dashboard; Definition and Scope, by Connectivity & Data Integration
TABLE 69: U.S. Connected Diabetes Care Devices Market, by Connectivity & Data Integration, 2021–2035 (US$ Billion)
TABLE 70: U.S. Connected Diabetes Care Devices Market: Segment Share Analysis, by Connectivity & Data Integration, 2025 & 2035 (%)
TABLE 71: U.S. Connected Diabetes Care Devices Market: Bluetooth-Connected Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. Connected Diabetes Care Devices Market: NFC-Enabled Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Connected Diabetes Care Devices Market: Cloud-Connected Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Connected Diabetes Care Devices Market: Interoperable Diabetes Device Ecosystems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Connected Diabetes Care Devices Market: Multi-Protocol Connected Ecosystems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Connected Diabetes Care Devices Market: Distribution Channel Snapshot, 2025
TABLE 77: Segment Dashboard; Definition and Scope, by Distribution Channel
TABLE 78: U.S. Connected Diabetes Care Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 79: U.S. Connected Diabetes Care Devices Market: Segment Share Analysis, by Distribution Channel, 2025 & 2035 (%)
TABLE 80: U.S. Connected Diabetes Care Devices Market: Retail & Specialty Pharmacies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. Connected Diabetes Care Devices Market: Durable Medical Equipment Suppliers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. Connected Diabetes Care Devices Market: Direct-to-Consumer & Manufacturer Fulfillment Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. Connected Diabetes Care Devices Market: Hospital & Clinic Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. Connected Diabetes Care Devices Market: E-Commerce & Digital Pharmacy Channels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: U.S. Connected Diabetes Care Devices Market: Regional Snapshot, 2025
TABLE 86: Segment Dashboard; Definition and Scope, by Geography
TABLE 87: U.S. Connected Diabetes Care Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 88: U.S. Connected Diabetes Care Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 89: U.S. Connected Diabetes Care Devices Market: Regional Diabetes Prevalence and Addressable Patient Analysis
TABLE 90: U.S. Connected Diabetes Care Devices Market: Regional CGM and Automated Insulin Delivery Adoption Analysis
TABLE 91: U.S. Connected Diabetes Care Devices Market: Regional Reimbursement, Pharmacy and DME Dynamics
TABLE 92: West Region U.S. Connected Diabetes Care Devices Market: Regional Overview and Trends
TABLE 93: West Region U.S. Connected Diabetes Care Devices Market: Key Manufacturers and Commercial Ecosystem
TABLE 94: West Region U.S. Connected Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 95: West Region U.S. Connected Diabetes Care Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 96: West Region U.S. Connected Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 97: West Region U.S. Connected Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 98: West Region U.S. Connected Diabetes Care Devices Market, by Connectivity & Data Integration, 2021–2035 (US$ Billion)
TABLE 99: West Region U.S. Connected Diabetes Care Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 100: California Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Washington Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Arizona Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: Colorado Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Oregon Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Utah Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Nevada Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: New Mexico Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Idaho Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Montana Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 110: Wyoming Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 111: Alaska Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 112: Hawaii Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Northeast Region U.S. Connected Diabetes Care Devices Market: Regional Overview and Trends
TABLE 114: Northeast Region U.S. Connected Diabetes Care Devices Market: Key Manufacturers and Commercial Ecosystem
TABLE 115: Northeast Region U.S. Connected Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 116: Northeast Region U.S. Connected Diabetes Care Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 117: Northeast Region U.S. Connected Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 118: Northeast Region U.S. Connected Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 119: Northeast Region U.S. Connected Diabetes Care Devices Market, by Connectivity & Data Integration, 2021–2035 (US$ Billion)
TABLE 120: Northeast Region U.S. Connected Diabetes Care Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 121: New York Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Massachusetts Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: New Jersey Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: Pennsylvania Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Connecticut Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: Maine Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: Vermont Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 128: New Hampshire Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Rhode Island Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Delaware Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: South Region U.S. Connected Diabetes Care Devices Market: Regional Overview and Trends
TABLE 132: South Region U.S. Connected Diabetes Care Devices Market: Key Manufacturers and Commercial Ecosystem
TABLE 133: South Region U.S. Connected Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 134: South Region U.S. Connected Diabetes Care Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 135: South Region U.S. Connected Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 136: South Region U.S. Connected Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 137: South Region U.S. Connected Diabetes Care Devices Market, by Connectivity & Data Integration, 2021–2035 (US$ Billion)
TABLE 138: South Region U.S. Connected Diabetes Care Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 139: Texas Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Florida Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Georgia Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: North Carolina Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Tennessee Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: South Carolina Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Alabama Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Mississippi Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Louisiana Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Arkansas Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Kentucky Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Oklahoma Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Virginia Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: Maryland Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: West Virginia Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: Midwest Region U.S. Connected Diabetes Care Devices Market: Regional Overview and Trends
TABLE 155: Midwest Region U.S. Connected Diabetes Care Devices Market: Key Manufacturers and Commercial Ecosystem
TABLE 156: Midwest Region U.S. Connected Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 157: Midwest Region U.S. Connected Diabetes Care Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 158: Midwest Region U.S. Connected Diabetes Care Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 159: Midwest Region U.S. Connected Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 160: Midwest Region U.S. Connected Diabetes Care Devices Market, by Connectivity & Data Integration, 2021–2035 (US$ Billion)
TABLE 161: Midwest Region U.S. Connected Diabetes Care Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 162: Illinois Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: Ohio Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: Michigan Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 165: Minnesota Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 166: Indiana Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: Wisconsin Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 168: Missouri Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 169: Iowa Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 170: Kansas Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 171: Nebraska Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 172: North Dakota Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 173: South Dakota Connected Diabetes Care Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 174: U.S. Connected Diabetes Care Devices Market: Competitive Landscape Snapshot, 2025
TABLE 175: U.S. Connected Diabetes Care Devices Market: Key Company Market Share Analysis, 2025
TABLE 176: U.S. Connected Diabetes Care Devices Market: Company Positioning Matrix
TABLE 177: U.S. Connected Diabetes Care Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 178: U.S. Connected Diabetes Care Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 179: U.S. Connected Diabetes Care Devices Market: Interoperability, Reimbursement and Distribution Benchmarking
TABLE 180: Abbott Diabetes Care: Company Profile
TABLE 181: Dexcom, Inc.: Company Profile
TABLE 182: Medtronic Diabetes: Company Profile
TABLE 183: Insulet Corporation: Company Profile
TABLE 184: Tandem Diabetes Care, Inc.: Company Profile
TABLE 185: Beta Bionics, Inc.: Company Profile
TABLE 186: Sequel Med Tech, LLC: Company Profile
TABLE 187: Senseonics Holdings, Inc.: Company Profile
TABLE 188: Ascensia Diabetes Care: Company Profile
TABLE 189: Roche Diabetes Care: Company Profile
TABLE 190: LifeScan, Inc.: Company Profile
TABLE 191: embecta Corp.: Company Profile
TABLE 192: Novo Nordisk A/S: Company Profile
TABLE 193: Eli Lilly and Company: Company Profile
TABLE 194: Ypsomed Holding AG: Company Profile
TABLE 195: Glooko, Inc.: Company Profile
TABLE 196: DarioHealth Corp.: Company Profile
TABLE 197: Teladoc Health / Livongo: Company Profile
TABLE 198: Omada Health, Inc.: Company Profile
TABLE 199: Tidepool: Company Profile
TABLE 200: AgaMatrix, Inc.: Company Profile
TABLE 201: Trividia Health, Inc.: Company Profile
TABLE 202: i-SENS, Inc.: Company Profile
TABLE 203: Prodigy Diabetes Care, LLC: Company Profile
TABLE 204: Modular Medical, Inc.: Company Profile
TABLE 205: U.S. Connected Diabetes Care Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 206: U.S. Connected Diabetes Care Devices Market: Disruptive Technologies Impact Matrix
TABLE 207: U.S. Connected Diabetes Care Devices Market: Emerging Business Trends
TABLE 208: U.S. Connected Diabetes Care Devices Market: Business Opportunities for Startups and Existing Players
TABLE 209: U.S. Connected Diabetes Care Devices Market: Investment Prioritization Matrix
TABLE 210: U.S. Connected Diabetes Care Devices Market: Technology Adoption Roadmap, 2026–2035
TABLE 211: U.S. Connected Diabetes Care Devices Market: Connected Diabetes Device White-Space Analysis
TABLE 212: U.S. Connected Diabetes Care Devices Market: Market Consolidation and M&A Outlook
TABLE 213: U.S. Connected Diabetes Care Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 214: U.S. Connected Diabetes Care Devices Market: Strategic Recommendations for Hospitals, Endocrinology Clinics and Primary Care Networks
TABLE 215: U.S. Connected Diabetes Care Devices Market: Strategic Recommendations for Commercial Payers and Healthcare Plans
TABLE 216: U.S. Connected Diabetes Care Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 217: U.S. Connected Diabetes Care Devices Market: Strategic Recommendations for Pharmacies, DME Suppliers and Channel Partners
TABLE 218: U.S. Connected Diabetes Care Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 219: U.S. Connected Diabetes Care Devices Market: Go-to-Market Strategy Considerations
TABLE 220: U.S. Connected Diabetes Care Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 221: U.S. Connected Diabetes Care Devices Market: Interoperability and Partnership Strategy
TABLE 222: U.S. Connected Diabetes Care Devices Market: State and Regional Commercial Prioritization
TABLE 223: U.S. Connected Diabetes Care Devices Market: Pricing and Reimbursement Strategy
TABLE 224: U.S. Connected Diabetes Care Devices Market: Patient Acquisition and Retention Strategy
TABLE 225: U.S. Connected Diabetes Care Devices Market: Scope Limitation
TABLE 226: U.S. Connected Diabetes Care Devices Market: Data Use Limitation
TABLE 227: U.S. Connected Diabetes Care Devices Market: Market Definition Limitation
TABLE 228: U.S. Connected Diabetes Care Devices Market: Forecasting Limitation
TABLE 229: U.S. Connected Diabetes Care Devices Market: Regulatory and Reimbursement Limitation
TABLE 230: U.S. Connected Diabetes Care Devices Market: Legal Disclaimer
TABLE 231: U.S. Connected Diabetes Care Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Connected Diabetes Care Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: U.S. Connected Diabetes Care Devices Market Ecosystem
FIGURE 4: Stakeholder Ecosystem Analysis
FIGURE 5: Market Attractiveness Analysis
FIGURE 6: Market Dynamics
FIGURE 7: Innovation & Patent Landscape, 2021–2025
FIGURE 8: Clinical Workflow Economics Framework
FIGURE 9: Patient Lifetime Value and Recurring Consumables Economics Framework
FIGURE 10: Payer, Pharmacy and DME Decision Framework
FIGURE 11: Connected Diabetes Device Adoption Curve
FIGURE 12: Value Chain Analysis
FIGURE 13: Supply Chain Analysis
FIGURE 14: PESTEL Analysis
FIGURE 15: Porter’s Five Forces Analysis
FIGURE 16: FDA Regulatory and CMS Reimbursement Landscape
FIGURE 17: U.S. Connected Diabetes Care Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 18: U.S. Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 19: U.S. Connected Diabetes Care Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 20: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 21: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Continuous Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Connected Insulin Pumps & Automated Insulin Delivery Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Connected Blood Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Smart Insulin Pens & Connected Injection Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Device-Linked Software, Controllers & Data Hubs Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 28: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Continuous Glucose Monitoring Application Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Automated Insulin Delivery Application Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Connected Multiple Daily Injection Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Remote Diabetes Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Metabolic & Preventive Glucose Monitoring Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 35: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Homecare & Individual Patients Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Hospitals & Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Endocrinology & Diabetes Specialty Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Primary Care Practices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Remote Care & Diabetes Management Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Connectivity & Data Integration Segment Market Share Analysis, 2025 & 2035
FIGURE 42: Connectivity & Data Integration Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Bluetooth-Connected Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: NFC-Enabled Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Cloud-Connected Platforms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Interoperable Diabetes Device Ecosystems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Multi-Protocol Connected Ecosystems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Distribution Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 49: Distribution Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Retail & Specialty Pharmacies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Durable Medical Equipment Suppliers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Direct-to-Consumer & Manufacturer Fulfillment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Hospital & Clinic Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: E-Commerce & Digital Pharmacy Channels Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 56: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: West Region U.S. Connected Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 58: West Region Market Share Analysis by State, 2025
FIGURE 59: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: California Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Washington Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Arizona Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Colorado Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Oregon Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Utah Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Nevada Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: New Mexico Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Idaho Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Montana Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Wyoming Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Alaska Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Hawaii Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Northeast Region U.S. Connected Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 74: Northeast Region Market Share Analysis by State, 2025
FIGURE 75: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: New York Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Massachusetts Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: New Jersey Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Pennsylvania Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Connecticut Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Maine Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Vermont Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: New Hampshire Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Rhode Island Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Delaware Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: South Region U.S. Connected Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 87: South Region Market Share Analysis by State, 2025
FIGURE 88: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Texas Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Florida Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Georgia Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: North Carolina Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Tennessee Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: South Carolina Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Alabama Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Mississippi Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Louisiana Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Arkansas Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Kentucky Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Oklahoma Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Virginia Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Maryland Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: West Virginia Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Midwest Region U.S. Connected Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 105: Midwest Region Market Share Analysis by State, 2025
FIGURE 106: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Illinois Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Ohio Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Michigan Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Minnesota Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Indiana Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Wisconsin Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Missouri Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Iowa Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Kansas Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Nebraska Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: North Dakota Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: South Dakota Connected Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 120: Company Positioning Matrix
FIGURE 121: Key Player Product Portfolio Benchmarking
FIGURE 122: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 123: Connected Diabetes Device Interoperability and Ecosystem Positioning
FIGURE 124: U.S. Connected Diabetes Care Devices Innovation Roadmap
FIGURE 125: Next-Generation CGM and Extended-Wear Sensor Adoption Roadmap
FIGURE 126: Automated Insulin Delivery and Type 2 Diabetes Expansion Roadmap
FIGURE 127: OTC Continuous Glucose Monitoring Opportunity Map
FIGURE 128: Smart Insulin Pen and Connected Injection Growth Roadmap
FIGURE 129: Future Market Scenario Analysis, 2026–2035
FIGURE 130: Disruptive Technologies Impact Matrix
FIGURE 131: Emerging Business Trends Matrix
FIGURE 132: Investment Prioritization Matrix
FIGURE 133: Strategic Growth Roadmap for U.S. Connected Diabetes Care Device Companies
FIGURE 134: Go-to-Market Strategy Framework
FIGURE 135: Product Positioning and Portfolio Expansion Framework
FIGURE 136: Regional Commercial Prioritization Framework
FIGURE 137: Reimbursement, Pharmacy and DME Market Access Framework
FIGURE 138: Patient Acquisition and Retention Framework
FIGURE 139: Report Scope, Forecasting and Disclaimer Framework